Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock Short Interest Report for September

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a large decrease in short interest in September. As of September 30th, there was short interest totaling 119,457 shares, a decrease of 36.4% from the September 15th total of 187,942 shares. Based on an average daily trading volume, of 69,825 shares, the days-to-cover ratio is currently 1.7 days. Currently, 6.6% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has a consensus rating of “Sell”.

Aptevo Therapeutics Trading Down 4.7%

Shares of Aptevo Therapeutics stock traded down $0.08 during midday trading on Friday, reaching $1.62. The company had a trading volume of 31,117 shares, compared to its average volume of 42,855. The stock has a fifty day simple moving average of $2.18 and a 200 day simple moving average of $3.77. Aptevo Therapeutics has a 1-year low of $1.37 and a 1-year high of $29.70. The company has a market capitalization of $2.93 million, a price-to-earnings ratio of -0.03 and a beta of 1.67.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) EPS for the quarter, topping analysts’ consensus estimates of ($6.02) by $0.71. Sell-side analysts expect that Aptevo Therapeutics will post -17.04 earnings per share for the current year.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to harness the immune system by directing immune cells toward specific disease-associated targets.

Aptevo’s pipeline is built primarily around its proprietary ADAPTIR bispecific antibody technology, which is intended to create therapeutic antibodies capable of binding to two different targets.